The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
- Registration Number
- NCT01157260
- Lead Sponsor
- Ewha Womans University
- Brief Summary
Indoxyl sulfate (IS) is a uremic toxin that accelerates the progression of chronic kidney disease (CKD). AST-120 (Kremezin®; Kureha Corporation, Tokyo, Japan) removes indole, which is the precursor of IS, in the intestine, and reduces the accumulation of IS. This drug has been shown to retard the deterioration of renal function in CKD patients through reducing the levels of IS.
IS was reported to promote aortic calcification and stimulate the proliferation of vascular smooth muscle cells (VSMC). IS also inhibits endothelial proliferation and wound repair. With this background, the investigators will performed the study whether AST-120 improve the endothelial dysfunction in CKD patients.
- Detailed Description
The purpose of this study is to examine whether Kremezin, Indoxyl sulfate lowering agent improve endothelial dysfunction in stage 3,4 chronic kidney disease patients
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
- Patients with Chronic kidney disease (Stage3 - Stage4)
- Patients who are able and willing to understand, sign and date an informed consent document, and authorize access to protected health information
- Acute gastric or duodenal ulcer
- Severe constipation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description AST-120 Kremezin AST-120 administration 2g three times a day
- Primary Outcome Measures
Name Time Method Changes of FMD(Flow Mediated Dilatation) 6 months FMD (Flow Mediated Dilatation): percent change of FMD response to hyperemia and after sublingual nitroglycerin on brachial artery.
- Secondary Outcome Measures
Name Time Method Level of Indoxyl Sulfate 3 months, 6 months
Trial Locations
- Locations (1)
Ewha Womans University Mokdong Hospital
🇰🇷Seoul, Korea, Republic of